AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03665077 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Initial SWE ultrasound
Description: At baseline, patients will undergo a sheer wave elastrography (SWE) ultrasound of their hands including wrists.
Study NCT03665077 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Blood draw at three months
Description: Blood drawn at three months to evaluate oxylipins.
Study NCT03665077 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Blood draw at six months
Description: Blood drawn at six months to evaluate oxylipins.
Study NCT03665077 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: SWE ultrasound at six months
Description: SWE ultrasound at six months to evaluate tendon stiffness.
Study NCT01826097 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: La-Z-Boy Massage Chair Vibration Effect on Bladder Cancer Cell Concentration
Study NCT02649517 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Endomyocardial biopsy
Description: Endomyocardial biopsy will be performed through a puncture in the femoral vein. 3-6 samples taken under the control of myocardial echocardiography or flyuroskopii. Samples of biopsy material then transmitted Pathomorphology for immunohistochemistry, light microscope.
Study NCT00822770 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Filgrastim
Description: Dose of 10 mcg/kg subcutaneous injection beginning on day -9 daily for 6 days.
Study NCT00822770 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Dose of 40 mg/m\^2 beginning on Day -6 for four consecutive days.
Study NCT03961516 — intervention group
Intervention type: DEVICE
Intervention: Frequently Sampled Oral Glucose Tolerance Test and CGM
Description: Patients will undergo a 2 hour frequently sampled oral glucose tolerance test while wearing an active FreeStyle Libre Pro sensor. Using as a tool to collect data.
Study NCT03961516 — intervention group
Intervention type: RADIATION
Intervention: MRI Pancreas and Liver
Description: Patients will undergo an MRI of the pancreas and liver
Study NCT04462822 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate 250 mcg and salmeterol xinafoate 50 mcg/Respirent
Description: 2 inhalations of Test and Reference product in each study period
Study NCT04462822 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ADVAIR DISKUS® 250/50
Description: 2 inhalations of Test and Reference product in each study period
Study NCT02226263 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: probiotics Lactobacillus acidophilus boucardii
Description: Using sterile technique, the probiotic with 1x109 \[CFU\] Lactobacillus acidophilus boucardii strain was added at a dose of 125 mg/ kg/dose twice daily for 4 weeks to fresh supplement breast milk or formula for preterm infants.
Study NCT01716520 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Umeclidinium/Vilanterol 62.5/25 mcg
Description: Umeclidinium/Vilanterol 62.5/25 mcg once daily in the morning via novel dry powder inhaler (NDPI)
Study NCT01716520 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Umeclidinium 62.5 mcg
Description: Umeclidinium 62.5 mcg once daily in the morning via novel dry powder inhaler (NDPI)
Study NCT01716520 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vilanterol 25 mcg
Description: Vilanterol 25 mcg once daily in the morning via novel dry powder inhaler (NDPI)
Study NCT00178646 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botox
Description: Botox 75-150 units, single treatment only
Study NCT00178646 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Botox
Description: Botox 75-150 units, single treatment only
Study NCT00178646 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Botox
Description: Botox 75-150 units, single treatment only
Study NCT02072070 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TissueGene-C
Description: TissueGene-C at 1.8 x 10\^7 cells
Study NCT02072070 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo control(Normal Saline)
Study NCT01603407 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: daily prednisone (0.75 mg/kg/day) tablets for 36-60 months
Study NCT01603407 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: intermittent prednisone (0.75 mg/kg/day, 10 days on, 10 days off) tablets for 36 to 60 months
Study NCT01603407 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Deflazacort
Description: daily deflazacort (0.9 mg/kg/day) tablets for 36-60 months
Study NCT03376113 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: the volitional help sheet
Description: A sheet includes two columns: one shows critical situations that easily trigger self-harm; other one shows appropriate solutions for patients to prevent self-harm.
Study NCT00822770 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Busulfan
Description: Dose of 130 mg/m\^2 for four consecutive days, immediately after completion of Fludarabine.
Study NCT00822770 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Allogeneic blood stem cell transplant
Description: Stem Cell Infusion (Bone marrow or PBPC)
Study NCT00822770 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATG (Thymoglobulin)
Description: Dose(s) of 0.5 mg/kg on day -3; of 1.5 mg/kg on day -2; and of 2 mg/kg on day -1. Given only to patients with unrelated donors.
Study NCT04647838 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tepotinib
Description: Tepotinib 500mg (2 tablets of 250mg) per day D1-21 orally, once daily
Study NCT01975298 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Laquinimod
Description: Oral Administration
Study NCT01975298 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Avonex®
Description: Interferon β1A 30 μg/0.5mL administered Intra Muscular
Study NCT02917772 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab/Ipilimumab
Description: * Induction: Mono-Therapy with Nivolumab (240 mg i.V. / Q2W x 8)~* If CR/PR: Nivolumab Maintenance Mono-Therapy (240 mg i.V. / Q2W)~* If SD/PD: Nivolumab/Ipilimumab Boost 1+2-Combination Therapy (Nivo 3 mg/kg i.V. and Ipi 1 mg/kg i.V. / Q3W x 2)~* If CR/PR: Nivolumab Maintenance Mono-Therapy (240 mg i.V. / Q2W)~* If SD/PD: Nivolumab/Ipilimumab Boost 3+4-Combination Therapy (Nivo 3 mg/kg i.V. and Ipi 1 mg/kg i.V. / Q3W x 2)~* If CR/PR/SD: Nivolumab Maintenance Mono-Therapy (240 mg i.V. / Q2W)
Study NCT00790205 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sitagliptin
Description: Sitagliptin, one 50 mg or one 100 mg tablet (dose dependant on renal function) orally, once daily.
Study NCT00790205 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablet matching the 50 mg or 100 mg sitagliptin tablet, orally, once daily.
Study NCT00508989 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Niacin-ER
Description: 500 mg daily for 4 weeks, 1000 mg daily for 4 weeks, and 1500 mg daily for 4 weeks
Study NCT00508989 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 500 mg daily for 4 weeks, 1000 mg daily for 4 weeks, and 1500 mg daily for 4 weeks
Study NCT00508989 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: L-NMMA
Study NCT00508989 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetylcholine
Study NCT01368471 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MGuard
Description: MGuard™ stent comprises a balloon-expandable, thin-strut stainless steel (316L) bare metal stent platform (strut width 100 µm) with mesh sleeve fibers of polyethyleneterephtalate (fiber width of 20 µm) attached to its outer surface. These fibers act like a net (aperture size 150 x 180 µm) preventing distal embolization of the plaque debris/thrombus placed between the vessel wall and the stent.
Study NCT01368471 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Control BMS or DES
Description: Control BMS or DES
Study NCT01932476 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Gluten Challenge
Description: Three-day gluten containing dietary challenge.
Study NCT01932476 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: SHAM_COMPARATOR
Intervention: Sham Challenge
Description: Three-day sham (gluten free) dietary challenge
Study NCT03998722 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vagivital
Description: Vagivital once Daily for 12 weeks
Study NCT02016209 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nanoparticle albumin-bound paclitaxel
Description: Neoadjuvant chemotherapy of nanoparticle albumin-bound paclitaxel in stage Ⅱ B and IIIA non-small cell lung cancer
Study NCT04484584 — intervention group
Intervention type: OTHER
Intervention: complex decongestive therapy
Description: Manual lymphatic drainage Manuel lymphatic drainage therapeutic technique is used for reducing edema and symptoms related with edema by accelerating lymphatic drainage. The aim of massage along the extremity is to provide fluid drainage.Manuel lymphatic drainage stimulates the internal contraction of lymphatic channels. If interstitial space concentration of protein is reduced, it provides drainage of obstructed lymph fluid from local lymph nodes.
Study NCT01355640 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: breast-feeding
Description: Mothers lay on the side of the bed comfortably with their infants in their arms after the infants' soiled diapers were changed. Mothers breast-fed their babies. The study was initiated when the infants were observed to have a large amount of areola in their mouth, with flanged lips and active jaw movements. Then two minutes after the breast-feeding, an experienced technician began to do heel lance, heel lance was given by the same experienced technician.Mothers breast-fed their babies two minutes before, during and eight minutes after the heel lance. Throughout the whole procedure, mothers were encouraged to continue breast-feeding when the babies stopped sucking and/or began to cry.
Study NCT01355640 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: non-nutritive sucking
Description: Mothers lay on the side of the bed comfortably with their infants in their arms after the infants' soiled diapers were changed. Each mother in this group was given a vacuum pacifier( the brand is Goodbaby) to console her baby. Heel lance was given by the same experienced technician. The study was initiated when the infants can suck the pacifier and hold it by himself without others' help. This generally requires half or one minute. Then two minutes after non-nutritive sucking, an experienced technician began to do heel lance. Babies sucked the pacifier two minutes before, during and eight minutes after heel lance. Throughout the whole procedure, mothers were encouraged to continue non-nutritive sucking when the babies stopped sucking and/or began to cry.
Study NCT00643617 — intervention group
Intervention type: RADIATION
Group type: OTHER
Intervention: CyberKnife Stereotactic Radiosurgery - Low Risk
Description: 38 Gy delivered in 4 fractions of 9.5 Gy per fraction with a radial margin of 2 mm around the prostate
Study NCT00643617 — intervention group
Intervention type: RADIATION
Group type: OTHER
Intervention: CyberKnife Stereotactic Radiosurgery - Intermediate Risk
Description: 38 Gy delivered in 4 fractions of 9.5 Gy per fraction with a radial margin of 5mm posterolaterally
Study NCT02119897 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Low Level Light Therapy
Study NCT01512797 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sitagliptin phosphate
Description: 100 mg/day orally
Study NCT01512797 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1 Placebo Pill per day
Study NCT03933462 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: InnoSpire Go
Description: Participants will use for 30 days.
Study NCT03933462 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Jet Nebulizer
Description: Participants will use for 30 days.
Study NCT02465736 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: 25mg/ m2 Docetaxel dose administered on days 1, 8, 15, and 22.
Study NCT02465736 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: 25mg/ m2 on days 1, 8, 15 and 22.
Study NCT02465736 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation
Description: Patient will receive 4 weeks of radiation therapy (44 Gy/20 fractions).
Study NCT02465736 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgery
Description: McKeown esophagectomy, Ivor Lewis esophagectomy or minimally invasive esophagectomy will be performed 4-8 weeks after chemoradiotherapy. Two-field lymphadenectomy with total mediastinal lymph node dissection is performed during surgery.
Study NCT02465736 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vinorelbine
Description: 25mg/ m2 on days 1, 8 of each cycle (i.e. every 21 days).
Study NCT02465736 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: 75mg/ m2 on day 1 of each cycle only (i.e. every 21 days).
Study NCT00150618 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SPD503 (1 mg)
Study NCT00150618 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SPD503 (2 mg)
Study NCT00150618 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SPD503 (3 mg)
Study NCT00150618 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SPD503 (4 mg)
Study NCT00150618 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT00382447 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: standard nebulizer
Description: Standard small volume nebulizer for aerosolized medication delivery
Study NCT00382447 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: breath actuated nebulizer
Description: Nebulizer that dispenses medication only during the inspiratory phase
Study NCT06202976 — intervention group
Intervention type: OTHER
Intervention: Secondary data collection
Description: clinical data
Study NCT02813044 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: total intravenous anesthesia (TIVA)
Description: In the TIVA group,anesthesia is induced and maintained by effect-site target controlled infusion of propofol and remifentanil.
Study NCT02813044 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: inhalation anesthesia group
Description: In the inhalation anesthesia group, anesthesia is induced by pentothal sodium 4-6mg/kg and remifentanil 1 μg/kg, and then maintained with end-tidal sevoflurane concentration of 0.8 to 1 MAC and continuous infusion of remifentanil at 0.1-0.3μg/kg/min.
Study NCT00656045 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dietary
Description: All participants in the investigation will receive a standard 8-week behavioral obesity intervention with 8 weekly, 1 hour group counseling and education sessions. The intervention will include a reduced caloric prescription (1200-1500 kcal/day) and fat gram prescription (30% or less kcals from fat).
Study NCT03267342 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: One-on-one financial counseling
Description: Clients will be given access to one-on-one financial counseling, provided by trained peer specialists, initially working under the guidance of the project director. The Consumer Financial Protection Bureau's Your Money, Your Goals: Financial Empowerment Toolkit for Social Services Programs (21) will be used as a reference during counseling sessions, with a view to developing a manual based on clients' existing experiences and coping strategies, such that the desired behavior change is manageable, realistic, and based on real-life possibilities rather than idealized circumstances which may be far from the reality of people's lives. Counseling will in all cases be responsive to clients' particular needs and concerns, rather than following a predetermined sequence.
Study NCT03267342 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Peer support group
Description: Support groups, facilitated by peer specialists and guided initially by the project director, will be offered for clients interested in specific financial issues such as budgeting, managing benefits, wise spending, planning and saving. The peer support groups will focus on enabling clients to share their own experiences with finances.
Study NCT03267342 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Supported access to mainstream banking services
Description: Interested clients will be helped to open bank accounts at banks of their choice, and to manage associated tools such as Automatic Teller Machine (ATM) cards and online bill pay. Clients will also be advised regarding use of non-bank financial products such as prepaid cards and check cashers. Representatives from both bank and non-bank providers will be invited to come in and talk with clients about the services they offer, and clients will also be invited to visit the facilities to be guided around the available services.
Study NCT03267342 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: A matched savings account
Description: Clients will have the option of joining a savings club, which will combine group meetings, facilitated by a peer specialist under the initial guidance of the project director, and regular savings deposits towards specified goals. Clients will be offered a limited savings match as an incentive to achieve their savings goal (for example, the savings club will offer a 50% match on any money saved within a specified time period towards a specific goal, up to a maximum of a $100 match).
Study NCT06484946 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: aquatic occupational therapy
Description: Each week, the children participated in a 45-minute aquatic occupational therapy group that consisted of warmup on land, 30 mins of sensory activities in the water, and 10 mins of social activity in the water
Study NCT04383756 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Donor Blood
Description: Up to 4 units (each unit contains 350mL) of leukoreduced donor whole blood
Study NCT04383756 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Banked Blood
Description: Up to 350mL of Allogenic banked component blood transfusion in a 1:1:1 manner (packed red blood cells : plasma : platelets)
Study NCT01373775 — intervention group
Intervention type: OTHER
Intervention: Patient charts reviewing
Description: Reviewing chart and identifying risk factors
Study NCT00656045 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical Activity
Description: The Physical Activity arm will receive an activity goal (200 minutes/week of moderate-intense physical activity).
Study NCT00656045 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: TV Watching
Description: The TV Watching arm will receive a TV watching goal of watching less than 10 hours of TV/week.
Study NCT01081886 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PEAK PlasmaBlade 4.0
Description: The PEAK PlasmaBlade will be used for the entirety of the total knee replacement, including the skin incision.
Study NCT03106090 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: educational materials
Description: The eSCP includes a treatment summary section, a section detailing follow-up and test recommendations, a section on anticipated and potential side effects, as well as additional information specific to their experience/concerns. They will receive a patient education notebook outlining symptoms and their management that is tailored to those that the subject may be likely to experience during their survivorship care trajectory.
Study NCT03356613 — intervention group
Intervention type: OTHER
Intervention: Focus group
Description: An researcher in psychology will lead focus group on research views for paramedical staff
Study NCT03356613 — intervention group
Intervention type: OTHER
Intervention: test of the Geni tool
Description: The GenI tool built on paramedic's view will be tested.
Study NCT01081886 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Traditional Electrosurgery with scalpel
Description: Scalpel will be used for the skin incision and traditional electrosurgery for the subcutaneous dissection.
Study NCT01239784 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Home-based neurodevelopmental rehabilitation programme
Description: Participation in the study will require the parent and child to attend two assessment visits in addition to completing a series of parent and infant activities on a daily basis throughout the 10-week intervention period. The parent-led activities will include activities such as walking with the child, stacking blocks, rolling a ball to the child, hiding a toy under a blanket for the child to find, encouraging the child to kick a rattle while the child is lying on his/her back, or crawling or rolling in different directions.
Study NCT00969683 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Tracheal intubation
Description: Tracheal intubation using a Double lumen tube without a hook
Study NCT00969683 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tracheal intubation
Description: Tracheal intubation with a Double lumen tube with a hook
Study NCT02580747 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: anti-meso-CAR vector transduced T cells
Description: genetically engineered lymphocyte therapy
Study NCT03438682 — intervention group
Intervention type: DEVICE
Intervention: Essure
Description: Essure hysteroscopic sterilization